VIEW SYSTEMS INCORPORATED (OTCMKTS:VSYM) had a decrease of 71.8% in short interest. VSYM’s SI was 18,300 shares in February as released by FINRA. Its down 71.8% from 64,900 shares previously. It closed at $0.0019 lastly. It is down 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.
The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) is a huge mover today! The stock increased 8.96% or $0.38 during the last trading session, reaching $4.62. About 238,392 shares traded. GenMark Diagnostics, Inc. (NASDAQ:GNMK) has risen 116.11% since February 15, 2017 and is uptrending. It has outperformed by 99.41% the S&P500.The move comes after 5 months positive chart setup for the $253.15M company. It was reported on Feb, 15 by Barchart.com. We have $4.94 PT which if reached, will make NASDAQ:GNMK worth $17.72M more.
View Systems, Inc. designs, develops, and sells computer software and hardware used in conjunction with surveillance capabilities. The company has market cap of $620,739. The companyÂ’s services and products include ViewScan Concealed Weapons Detection System, a walk-through concealed weapons detector, which uses data sensing technology to pinpoint the location, size, and number of concealed weapons. It currently has negative earnings. The Company’s products also include the visual first responder system and the Viewmaxx digital video system.
Since August 15, 2017, it had 0 insider purchases, and 17 selling transactions for $592,848 activity. $12,068 worth of stock was sold by Kayyem Jon Faiz on Monday, August 21. Gleeson Michael also sold $18,267 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Monday, August 21. 4,000 shares were sold by Stier Eric, worth $20,200. $27,386 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) was sold by Mendel Scott. MASSARANY HANY also sold $78,539 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Monday, August 21. Williams Jennifer Anne also sold $1,872 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) shares. McNally James B. also sold $4,350 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) shares.
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company has market cap of $253.15 million. The firm provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It currently has negative earnings. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test.
Analysts await GenMark Diagnostics, Inc. (NASDAQ:GNMK) to report earnings on February, 27. They expect $-0.24 earnings per share, up 11.11% or $0.03 from last year’s $-0.27 per share. After $-0.28 actual earnings per share reported by GenMark Diagnostics, Inc. for the previous quarter, Wall Street now forecasts -14.29% EPS growth.